Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT Interest Expense
Cost of servicing the company's debt during the period.
Galectin Therapeutics Inc.NASDAQ: GALT
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense grows, but more slowly than its trailing trend
Q1 FY2026 interest expense of $1.99M rose 14.0% year over year, behind the +21.5% change in trailing-twelve-month interest expense. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at +92.2% a year.
Context
- Interest expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +14.0% toward the trailing-twelve-month pace of +21.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 7.33M USD
- Year-over-year change
- +32.3%
- 4-year CAGR
- +96.8%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.33M | +32.3% |
| FY2024 | 2024-12-31 | 5.54M | +98.4% |
| FY2023 | 2023-12-31 | 2.79M | +170.3% |
| FY2022 | 2022-12-31 | 1.03M | +111.2% |
| FY2021 | 2021-12-31 | 489K | — |
Interest Expense vs competitors
How GALT compares with its peers on the latest reported figures
- GALT's LTM Mar 2026 interest expense of $7.57M is the 2nd highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +21.5% is the 3rd highest of 4, against a peer median of +150.6%.
- Over three fiscal years its annual growth of +92.2% compares with a peer median of +13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.64M | — | -38.1% | — | |
| LTM Mar 2026 | $7.57M | +21.5% | +92.2% | — | |
| LTM Mar 2026 | $4.73M | +150.6% | -0.3% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $2.99M | -0.3% | +28.1% | — |
| LTM Mar 2026 | $2.7M | +29933.3% | +489.2% | 7508.3% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$206.5K | — | — | — |
| Peer median (excluding GALT) | $0 | +150.6% | +13.9% | 3754.2% | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.82M | 31.74M | 32.13M | 36.57M | 14.29M |
| Selling, General & Admin | 6.36M | 6.62M | 5.94M | 5.86M | 5.8M |
| Operating Expenses | 30.18M | 38.35M | 38.07M | 42.43M | 20.09M |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| EBITDA | (30M) | (37.71M) | (38.24M) | (41.47M) | (23.45M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (30.18M) | (38.35M) | (38.07M) | (42.43M) | (20.09M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3K | 52K | 230K | 338K | 126K |
| Interest Expense | 489K | 1.03M | 2.79M | 5.54M | 7.33M |
| Other Income / Expenses | (348K) | (424K) | (2.99M) | (4.61M) | (10.75M) |
| Income Before Tax | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| EPS (Diluted) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| Weighted Avg Shares | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
| Weighted Avg Shares (Diluted) | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.